Claims

1. A composition for use in preventing or treating diabetes, diabesity or diabetic complications, the composition comprising an oxyntomodulin analog as an active ingredient wherein the oxyntomodulin analog comprises the amino acid sequence selected from the group consisting of SEQ ID NOs: 24 to 26, and 28.

2. The composition of claim 1, wherein the oxyntomodulin analog is in the form of a conjugate with one selected from the group consisting of an immunoglobulin fragment, an antibody, elastin, albumin and fibronectin.

3. The composition of claim 2, wherein the conjugate is a conjugate in which the oxyntomodulin analog comprising the amino acid sequence selected from the group consisting of SEQ ID NOs: 24 to 26, and 28 is linked to an immunoglobulin Fc region through a non-peptidyl polymer.

4. The composition of claim 3, wherein the non-peptidyl polymer is selected from the group consisting of polyethylene glycol, polypropylene glycol, an ethylene glycol/propylene glycol copolymer, polyoxyethylated polyol, polyvinyl alcohol, polysaccharides, dextran, polyvinyl ethyl ether, PLA (polylactic acid), PLGA (polylactic-glycolic acid), lipid polymers, chitins, hyaluronic acid, and combinations thereof.

5. The composition of claim 3, wherein each end of the non-peptidyl polymer is linked to the immunoglobulin Fc region and the amine group or thiol group of the oxyntomodulin, respectively.

6. The composition of claim 1, further comprising a pharmaceutical agent showing preventive or therapeutic effects against diabetes, diabesity or diabetic complications.

7. The composition of claim 1, wherein the diabetes is insulin-dependent type 1 diabetes or insulin-independent type 2 diabetes.

8. The composition of claim 1, wherein the diabesity results from obesity.